The Quiet Technology Shaping Strategic Decisions In Healthcare

InnovationThe Quiet Technology Shaping Strategic Decisions In HealthcareByWenbin Jiang,Forbes Councils Member.for Forbes Technology CouncilCOUNCIL POSTExpertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. | Membership (fee-based)May 13, 2026, 09:00am EDTWenbin Jiang, CEO and Co-Founder of Cytek Biosciences, Inc. gettyAs someone who has spent the last decade driving the advancement of flow cytometry technology and its real-world applications, I have seen firsthand how profoundly this technology shapes outcomes beyond the lab. When leading a healthcare or biotech organization, you realize that every technology decision carries real strategic consequences. Yet some tools have an impact far beyond the lab, shaping outcomes in ways that directly affect research timelines, clinical trials and patient care.​Flow cytometry is one such technology. Though it rarely makes headlines, it underpins everything from immunotherapy to precision medicine, helping teams turn complex cellular data into decisions.​Executives who recognize where this technology can accelerate decisions and reduce risk can realize a real competitive advantage. In fact, the global market for flow cytometry, driven by the growing need for high-resolution cellular analysis and more precise clinical decision-making, is forecasted to grow to over $7.0 billion by 2030, at a compound annual growth rate of about 8.4%, according to Grand View Research.​From Lab Tool To Strategic Infrastructure​Just as the microscope became foundational to laboratory science, flow cytometry is now essential infrastructure for modern research and clinical insight.​By analyzing millions of individual cells and detecting subtle differences, it provides insights that guide therapy development, clinical trials and diagnostics. For leaders, the implications are clear:• Accelerated Drug Development: What once took years can now take days, as flow cytometry identifies the most promising...